Cover Image

PP 2.13 - 00160 Enhancing Tolerability and Efficacy of Latency Reversing Agents in "Kick and Kill" HIV Cure Approaches

Saved in:

Bibliographic Details
Main Authors:	J. Moran (Author), P. Wender (Author), J. Zack (Author), M. Marsden (Author)
Format:	Book
Published:	Elsevier, 2022-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

OP 2.8 - 00193 Enhancing PKC Modulator HIV Latency Reversing Agents
by: M. Marsden, et al.
Published: (2022)

HIV latency reversal using designed PKC modulators
by: M.D. Marsden, et al.
Published: (2017)

PP 5.4 - 00184 Optimization of Smac Mimetics as HIV-1 Latency Reversing Agents
by: L. Pache, et al.
Published: (2022)

Defining the Effects of PKC Modulator HIV Latency-Reversing Agents on Natural Killer Cells
by: Melanie Dimapasoc, et al.
Published: (2024)

PP 1.3 - 00022 Signaling pathways that activate P-TEFb to reverse HIV latency in CD4+ T cells
by: U. Mbonye, et al.
Published: (2022)

Optimisation of Smac mimetics as HIV-1 latency reversing agents
by: L. Pache, et al.
Published: (2019)

Evaluation of HIV latency reversal using designed PKC modulators in humanized BLT mice
by: M.D. Marsden, et al.
Published: (2015)

O3 Heme-arginate as a latency-reversing agent for HIV-1 cure
by: Michaela Madlenakova, et al.
Published: (2017)

23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal
by: T.M. Mota, et al.
Published: (2016)

PP 1.33 - 00167 Integrated single-cell multi-omic profiling of HIV latency reversal
by: A. Manickam, et al.
Published: (2022)

On-arcs with weighted point of type (n-13,n) in PG (2,13)
by: Makbola J, et al.
Published: (2006)

Differential effects of HIV latency-reversing agents on T cell phenotype and function: implications for HIV cure
by: G. Clutton, et al.
Published: (2015)

No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach
by: Jasmini Alagaratnam, et al.
Published: (2021)

PP 1.22 - 00120 Suppression of CD4+ T-cell-intrinsic immunity by HIV-1 latency-reversing HDACi
by: J. Kazmierski, et al.
Published: (2022)

The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review
by: Quinten Debrabander, et al.
Published: (2023)

PP 2.9 - 00125 Impact of latency reversal agents on estrogen receptor alpha gene and protein expression
by: C. Ceriani, et al.
Published: (2022)

PP 1.11 - 00075 Selective nuclear retention of spliced and unspliced HIV-1 mRNAs following latency reversal
by: E. Honeycutt, et al.
Published: (2022)

PP 1.10 - 00069 Isotretinoin enhances IL-15 mediated HIV latency reversal and reduces the inducible latent reservoir
by: J. Howard, et al.
Published: (2022)

OA4-4 Latency reversing agents induce HIV-1 protein expression in latently infected cells for cytotoxic T-lymphocyte antiviral recognition and killing
by: A. Ruiz, et al.
Published: (2016)

Sting agonist as a kick and kill agent to target the HIV reservoir
by: M. Mavigner, et al.
Published: (2019)

Combinatorial latency reversal activity of inhibitor of apoptosis antagonists with mechanistically distinct classes of HIV latency reversal agents
by: Shane D. Falcinelli, et al.
Published: (2019)

Approaches to discover latency-reversing agents
Published: (2015)

24 Thalidomide reverses latency of HIV-1 provirus
by: S. Samer, et al.
Published: (2016)

Identification of a promising new class of latency reversing agents
by: A. Gramatica, et al.
Published: (2017)

Novel SHIVs encoding transmitted/founder envs for latency and cure research
by: K. Bar, et al.
Published: (2017)

Novel SHIVs encoding transmitted/founder Envs for latency and cure research
by: A. Bauer, et al.
Published: (2019)

28 Dendritic cells programmed by inflammatory mediators can effectively induce both the immunologic 'kick' and 'kill' of latent HIV-1
by: J. Kristoff, et al.
Published: (2016)

Tissue-specific effects of latency-reversing agents on HIV transcriptional blocks in gut and blood
by: S. Telwatte, et al.
Published: (2019)

Latency-reversing agents and cellular activation affect antigen processing in primary CD4 T cells
by: J. Boucau, et al.
Published: (2015)

"Kill or Cure?": BBC broadcasts series on developing-country diseases
Published: (2004)

"Kill or Cure?": BBC broadcasts series on developing-country diseases

Co-culture of T-cells with dendritic cells facilitates HIV latency in proliferating CD4+ T-cells: implications for the establishment and reversal of latency
by: N. Kumar, et al.
Published: (2015)

Integration site-independent enhancement of latency reversal by HIV-1 Nef
by: X.T. Kuang, et al.
Published: (2017)

Cleavage and polyadenylation specific factor 6 is required for HIV latency reversal
by: Y. Zheng, et al.
Published: (2019)

PP 1.39 - 00086 The level of cell activation is associated with the pre-integrative latency of HIV linear DNA
by: H.M. Roux, et al.
Published: (2022)

A theoretical framework to guide clinical trial design to estimate efficacies of latency-reversing agents
by: R. Ke, et al.
Published: (2015)

Phorbol esters isolated from Croton megalobotrys reverse HIV latency ex vivo
by: I. Tietjen, et al.
Published: (2019)

Lnc(ing)RNAs to the "shock and kill" strategy for HIV-1 cure
by: Saikat Boliar, et al.
Published: (2021)

PP 1.36 - 00182 Effect of HIV-1C Transmitted/Founder Viruses 5'LTRand tat Genetic Variation on Viral Reservoir Size and Latency Reversal Potential
by: Shreyal Maikoo, et al.
Published: (2022)

No evidence of neuroaxonal injury following latency reversal with vorinostat and HIV-1 specific vaccination in the RIVER trial
by: J. Alagaratnam, et al.
Published: (2019)